EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of a casein glycomacropeptide‐based protein substitute, in the dietary management of NTBC‐induced tyrosinaemia in patients with alkaptonuria: A prospective open‐label study

Shirley Judd, Ali Hutton, Grace Thomas, Heather Hill

Journal of Human Nutrition and Dietetics · 2024

DOI: 10.1111/jhn.13360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Nutrition and Dietetics, 2024. Verfasst von Shirley Judd und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Alkaptonuria Centre, Liverpool, UK. Hauptthemen laut MEDLINE: Caseins, Cyclohexanones, Tyrosinemias, Nitrobenzoates. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vitaflo International Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

2‐(2‐Nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC) treatment of alkaptonuria (AKU) leads to increased blood tyrosine levels, causing skin issues and potentially sight‐threatening corneal keratopathy. Adherence to dietary management of NTBC‐induced tyrosinemia, a low‐protein diet with or without protein substitutes, can be difficult for patients. This 28‐day interventional study evaluated a low tyrosine casein glycomacropeptide (cGMP) protein substitute (TYR sphere)®, a 20 g protein equivalent, cGMP‐based protein substitute, in terms of adherence, palatability, usability, comparison to amino acid (AA)–based protein substitutes, gastrointestinal tolerance and metabolic control in adults with NTBC‐induced tyrosinaemia.

Methods

Four adults (mean 61.1 years, range 53.3–69.3 years) with AKU and NTBC‐induced tyrosinaemia were recruited from the United Kingdom National Alkaptonuria Centre (NAC). The cGMP protein substitute was prescribed based on individual nutritional requirements, replacing ≥1 AA‐based protein substitute. Participants recorded product‐related data in study diaries, using five‐point Likert scales and daily and weekly logs. To determine metabolic control, prestudy blood tyrosine levels were compared to weekly blood spot tests during the study.

Results

Median cGMP protein substitute adherence was 98%. Most participants rated palatability and usability positively, and preferred cGMP protein substitute to AA‐based products. There were no notable gastrointestinal changes, and metabolic control was maintained. Conclusions cGMP protein substitute is a palatable and well‐tolerated option in the dietary management of AKU patients with NTBC‐induced tyrosinaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaseinsCyclohexanonesTyrosinemiasNitrobenzoatesTyrosinePeptide FragmentsHumansMiddle AgedMaleProspective StudiesFemaleAgedDiet, Protein-RestrictedPatient Compliance

Stichwörter der Autor:innen

NTBCalkaptonuriadietary managementglycomacropeptidenitisinonetyrosinaemia

Substanzen

CaseinscaseinomacropeptideCyclohexanonesnitisinoneNitrobenzoatesTyrosinePeptide Fragments

Autor:innen und Institutionen

  • National Alkaptonuria Centre, Liverpool, UK.
  • Vitaflo International Ltd, Liverpool, UK.

Förderung

  • Vitaflo International Ltd

Zitieren

APA

Judd, S., Hutton, A., Thomas, G., & Hill, H. (2024). Evaluation of a casein glycomacropeptide‐based protein substitute, in the dietary management of NTBC‐induced tyrosinaemia in patients with alkaptonuria: A prospective open‐label study. Journal of Human Nutrition and Dietetics. https://doi.org/10.1111/jhn.13360

Vancouver

Judd S, Hutton A, Thomas G, Hill H. Evaluation of a casein glycomacropeptide‐based protein substitute, in the dietary management of NTBC‐induced tyrosinaemia in patients with alkaptonuria: A prospective open‐label study. Journal of Human Nutrition and Dietetics. 2024. doi:10.1111/jhn.13360

BibTeX
@article{Judd2024,
  author = {Judd, Shirley and Hutton, Ali and Thomas, Grace and Hill, Heather},
  title = {Evaluation of a casein glycomacropeptide‐based protein substitute, in the dietary management of NTBC‐induced tyrosinaemia in patients with alkaptonuria: A prospective open‐label study},
  journal = {Journal of Human Nutrition and Dietetics},
  year = {2024},
  doi = {10.1111/jhn.13360}
}
Kostenlos starten →